- BB
Authors: Adesola, Ridwan Olamilekan; Advisor: -; Participants: D’Souza, Joanna Nicole; Bello, Aisha Bisola; Mukwekwe, Varaidzo Joyline (2023) - In the current global scenario, the monkeypox virus has infected over 3000 individuals from endemic countries like Nigeria, along with non-endemic countries like the UK, Canada, the USA, etc. Based on the current information, it has been observed that monkeypox cases have primarily, though not exclusively, been found among men who have sex with men (MSM) in countries such as the UK. This article discusses the recent outbreak of monkeypox, its causes, and the various approaches to combat monkeypox infections.
|
- BB
Authors: Reuben, Rine Christopher; Advisor: -; Participants: Abunike, Sarah Adamma (2023) - The recent outbreaks of Marburg virus disease (MVD) in Guinea and Ghana have become a major public health concern not only to the West African sub-region but a threat to global health.
|
- BB
Authors: Haruna, Usman Abubakar; Advisor: -; Participants: Muhammad, Ahmad Dalhatu; Lucero-Prisno III, Don Eliseo (2023) - There have been multiple outbreaks of emerging infections since the turn of the century. A bulk of these diseases is caused by animals, including the Zika virus, Middle East Respiratory Syndrome (MERS), Ebola Virus Disease (EVD), Coronavirus Disease 2019 (COVID-19), Monkeypox (MPOX), and Adenovirus among others (Manirambona et al. 2022; Alarcon-Valdes et al. 2022). These diseases were formerly known to infect animals, but they now affect humans. We think that human activities such as land use and livestock practices, and the impact of climate change, are major contributing factors to the emergence and spread of viral zoonotic diseases. By addressing these root causes, we can reduce the risk of future outbreaks and improve public health.
|
 - BB
Authors: AbdelMassih, Antoine; Advisor: -; Participants: Sedky, Abrar; Shalaby, Ahmed; Shalaby, AlAmira-Fawzia; Yasser, Alia; Mohyeldin, Aya; Amin, Basma; Saleheen, Basma; Osman, Dina; Samuel, Elaria; Abdelfatah, Emmy; Albustami, Eveen; ElGhamry, Farida; Khaled, Habiba; Amr, Hana; Gaber, Hanya; Makhlouf, Ismail; Abdeldayem, Janna; El-Beialy, Jana Waleed; Milad, Karim; Sharkawi, Laila El; Abosenna, Lina; Safi, Madonna G.; AbdelKareem, Mariam; Shershaby, Meryam El (2022) - After the discovery of the SARS-CoV-2 variant, Omicron, that sporadically arose in November 2021, it was compared to the Delta variant that was discovered in May 2021 in terms of virulence and transmissibility. While Omicron has shown higher rates of transmission than the other variants, it showed less virulent symptoms with relatively mild disease. The Delta variant, however, has been associated with high virulence causing severe lower respiratory tract symptoms and reduced transmission rate (Kumar et al. 2021). This leaves us wondering; does COVID-19 agree with the trade-off hypothesis?
|
- BB
Authors: Gustavsen, Stefan; Advisor: -; Participants: Nordling, Mette Maria; Weglewski, Arkadiusz (2023) - The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has been leading to dramatic health, social and economic problems around the world. It was necessary to introduce worldwide vaccination program against SARS-CoV-2 virus. Vaccination of billions of people around the world leads to many questions about risk of vaccines and possible side effects. It is well known that acute disseminated encephalomyelitis (ADEM) is a rare, but possible complication of vaccines. Previously, cases of ADEM following various COVID-19 vaccines, including the vaccines from AstraZenica, Pfizer, Sputnik V, SinoVac, Moderna, Sinopharm, have been described. In this case report, we present the first documented case of ADEM following the COVID-19 vaccine Ad26.COV2.S from Johnson & Johnson.
|
- BB
Authors: Babatope, Tolulope; Advisor: -; Participants: Ilyenkova, Vera; Marais, Debbi (2023) - A total of 161 records identified from the four databases were exported into Rayyan systematic review software and duplicates were removed, leaving 148 records to be screened (Fig. 2). The kappa test of inter-rater agreement between reviewers was 0.83. Full-text screening was conducted to further assess the remaining 23 articles for eligibility before data extraction. Eight articles were excluded mainly due to being the wrong publication type (n = 4) or having the wrong outcome (n = 4). At the end of the process, 15 articles were eligible for inclusion in the review with an inter-rater agreement of κ = 0.95.
|
- BB
Authors: Singla, Shivali; Advisor: -; Participants: Goyal, Sachin (2022) - The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and safety of molnupiravir in clinical trials.
|
- BB
Authors: S. Amoo, Olufemi; Advisor: -; Participants: Onyia, Ngozi; I. Onuigbo, Tochukwu; U. Vitalis, Stephanie; Davies-Bolorunduro, Olabisi F.; Joy I. Oraegbu; Adeniji, Esther T.; Obi, Josephine C.; Abodunrin, Olusola N.; Ikemefuna, Amaka S.; Adegbola, Richard A.; Audu, Rosemary A.; Salako, Babatunde L. (2022) - Social and demographic characteristics of study participants
The descriptive statistics for all the patients with COVID-19 were summarized and are presented in Table 2. Among the 236 participants, 158 (66.9%) were males and 78 (33.1%) were females. The mean ± SD age of the SCP was 52.3 ± 16.9 years and 42.4 ± 17.2 years for the NSCP. Most of the participants were between 24 and 65 years of age.
|
- BB
Authors: Muhammad, Yasin Ali; Advisor: -; Participants: - (2022) - At the time of this writing, SARS-CoV-2 has reportedly claimed the lives of millions of people worldwide. However, there is still disagreement concerning the origin of SARS-CoV-2, its true nature, and the extent of its pathogenicity. Thus, the purpose of this manuscript is to highlight and critically analyze these differences so that research efforts can be geared toward addressing these concerns.
|
- BB
Authors: Suri, Arpita; Advisor: -; Participants: Singh, Naveen Kumar; Perumal, Vanamail (2022) - COVID-19 outbreak has engulfed different parts of the world, affecting more than 163 million people and causing more than 3 million deaths worldwide due to human transmission. Thus, it has become critical to identify the risk factors and laboratory parameters to identify patients who have high chances of worsening clinical symptoms or poor clinical outcomes. Therefore, the study aims to identify inflammatory markers that can help identify patients at increased risk for progression to critical illness, thus decreasing the risk of any mortality. Our study focussed on the predictive utility of C-reactive protein, Interleukin-6, D-dimer and Procalcitonin in assisting the management of COVID-19 patients with adverse clinical effects. Through literature search in electronic databases, we ...
|
